Can Finerenone Alter Glomerular Disease Trajectory? - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Can Finerenone Alter Glomerular Disease Trajectory?

A prespecified exploratory analysis of the FIND-CKD clinical trial examined kidney function, albuminuria, and kidney failure outcomes in 903 patients with glomerular diseases.

  • By

  • Kathryn Wighton

  • June 5, 2026

  • 4 min

Share

  • 1

    The FIND-CKD trial included 903 participants with glomerular diseases, assessing the effects of finerenone versus placebo.

  • 2

    Finerenone reduced the eGFR decline by 1.22 mL/min/1.73 m² per year after 3 months compared to placebo.

  • 3

    In the immunoglobulin A nephropathy subgroup, finerenone decreased urinary albumin-to-creatinine ratio by 47%.

  • 4

    Serious adverse events were similar between finerenone (20%) and placebo (21%) groups, with low rates of hyperkalemia.

  • 5

    The study faced limitations, including reliance on investigator-reported diagnoses and lack of biopsy confirmation for many participants.

Original Source(s)

Can Finerenone Alter Glomerular Disease Trajectory?

  • by Kathryn Wighton

  • June 5, 2026

Related Content

New CDC Report Tracks US Mortality Trends

The annual provisional report summarizes changes in mortality rates, demographic patterns, and leading causes of death during 2025.

Oral Aleniglipron Reduced Weight at 36 Weeks

In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.

Effect of Socioeconomic Status on SGLT2 Initiation in Heart Failure

A nationwide German claims analysis found lower initiation of guideline-recommended sodium-glucose cotransporter-2 inhibitors among women and patients living in lower-income municipalities.